What's Happening?
Quebec has added Rezurock (belumosudil tablets) to its list of publicly reimbursed medications for patients aged 12 and older with chronic graft-versus-host disease (GVHD) who have not responded to at least
two prior lines of systemic therapy. This decision follows Health Canada's approval in March 2023 and recommendations from Canada's Drug Agency and the Institute of Excellence in Health and Social Services. Chronic GVHD is a serious post-transplant complication affecting multiple organs, significantly impacting patients' quality of life.
Why It's Important?
The inclusion of Rezurock in Quebec's public drug plan represents a critical advancement in the treatment of chronic GVHD, offering new hope to patients and families affected by this challenging condition. Public coverage ensures broader access to this innovative therapy, potentially improving outcomes and quality of life for those with limited treatment options. This development underscores the importance of making advanced therapies accessible to patients through public health systems.
